MDGL
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals, Inc. (MDGL) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.
Quantitative Factor Evaluation • Updated
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | C+ (2.8) | B (3.3) | A- (4.0) | C (2.4) | C+ (2.6) | B- (3.0) |
| 2026-11-06 | C+ (2.7) | A- (3.9) | A- (4.0) | C+ (2.5) | C+ (2.7) | B (3.2) |
| 2026-10-30 | C+ (2.6) | A- (4.1) | A- (4.0) | C+ (2.8) | A+ (5.0) | B+ (3.7) |
| 2026-10-23 | C+ (2.6) | A- (4.1) | A- (4.0) | C (2.5) | A+ (5.0) | B+ (3.6) |
Showing the last month only. Subscribe for the full factor score history.
For more — Subscribe